The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; MSD K.K; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Ryo Sadachi
No Relationships to Disclose
 
Tadayoshi Hashimoto
No Relationships to Disclose
 
Nozomu Machida
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca Japan
Research Funding - MSD K.K (Inst)
 
Satoru Iwasa
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Yasuhide Yamada
Honoraria - Chugai Pharma; Eisai; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Janssen
Research Funding - Chugai Pharma; Daiichi Sankyo
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Olympus
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takaki Yoshikawa
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology
Research Funding - Lilly
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)